Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
IRCCS Azienda Ospedaliero-Universitaria di Bologna
The study is aimed at patients with NSCLC in whom plasma levels of particular biomarkers will be studied before and after treatment with chemotherapy and immunotherapy or immunotherapy alone.
In particular, the plasma levels of GDF15, FGF21, HN, Activin molecules and microRNAs involved in inflammatory processes, called inflammamiR, in particular of microRNA146, 126, 21, 188, 155, will be studied.
Assessments of cellular markers of leukocyte aging will also be performed (determination of telomere length is a widely used measure of biological aging)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with NSCLC in advanced stage (IIIB, IV)
Patients eligible for the treatment with single-agent immunotherapy (Pembrolizumab), or a chemo-immunotherapy combination among the approved ones for I line
Obtainment of the informations related to medical history and the possibility to have an adequate follow up
Obtainment of the informed consent
Age ≥ 18 years
You may not be if
Patients with psychiatric alterations, neurological diseases or other condistions that could not allow adhesion to study protocol and the obtainment of the ICF